Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2014

View Archived Issues

Baxter restructures agreement with Xenetic Biosciences and provides pipeline update

Researchers characterize antifungal activity EV-086

Glycopolymers used to uncover the mechanistic basis of tumor immunoprotection

Pazopanib demonstrates activity in patients with germ cell tumors

Sorafenib activity limited in patients with germ cell tumors

Chugai Pharmaceutical presents highlights of fourth quarter 2013

Phase II/III trial of Stallergenes' house dust mite immunotherapy tablets meets primary endpoint

AstraZeneca completes purchase of Bristol-Myers Squibb's global diabetes business

Burnet Institute receives grant to evaluate HIV test

Portola enters second collaboration with Bayer and Janssen for andexanet alfa

Chinese researchers present novel acetylcholinesterase inhibitors for Alzheimer's disease

New chimeric proteins patented by Biogen Idec and Amunix Operating

Omeros reports data from phase I trial of OMS-721

Phase Ib trial evaluates ONT-380 in breast cancer

Yong Guang Pharmaceutical discloses novel agents for cancer

U.S. group claims new HDAC4 inhibitors for Huntington's disease

Scientists in China synthesize new CETP inhibitors

Grastek obtains approval in Canada for grass pollen-induced allergic rhinitis

Tecfidera obtains approval in Europe for multiple sclerosis

Agios Pharmaceuticals opts for U.S. rights to IDH1 program

U.S. Navy approves phase I trial of Multikine in patients with HIV/HPV and perianal warts

FDA grants breakthrough therapy designation to eltrombopag

Tetrandrine demonstrates ability to protect against Ebola virus challenge in vivo

Ferrer collaborates with Ergomed and Ildong Pharmaceuticals for lorediplon

Kyowa Hakko Kirin initiates phase III study of ARQ-197 for HCC in Japan

Dainippon Sumitomo Pharma offers overview of third quarter of fiscal 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...